Monograph Details
|
|
Infections & Infestations
> Bacterial infections
|
|
LEVAQUIN INJ PREMIXED |
| Manufacturer |
|
Ortho-McNeil Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Quinolone. |
| Generic Name |
|
Levofloxacin 5mg/mL; soln for slow IV infusion; preservative-free. |
| Also |
• LEVAQUIN INJ CONCENTRATE
• LEVAQUIN ORAL SOLN
• LEVAQUIN TABS
|
| Indications |
|
Susceptible bacterial infections including acute sinusitis, acute exacerbations of chronic bronchitis, nosocomial or community-acquired pneumonia (CAP), UTIs, acute pyelonephritis, chronic bacterial prostatitis, skin and skin structure infections. Inhalation anthrax (post-exposure): to reduce incidence or progression of disease (see literature). |
| Children |
|
Inhalation anthrax (post–exposure): ≥6months: <50kg: 8mg/kg twice daily for 60 days; max 250mg/dose. >50kg: 500mg once daily for 60 days; |
| Adults |
|
≥18yrs: Regimen depends on pathogen type (see literature). Tabs: take with water. Oral soln: take on empty stomach. IV: infuse over 60 minutes (250mg or 500mg), or over 90 minutes (750mg). Bronchitis: 500mg once daily for 7 days. Nosocomial pneumonia: 750mg once daily for 7–14 days. CAP: 500mg once daily for 7–14 days or 750mg once daily for 5 days. Sinusitis: 500mg once daily for 10–14 days or 750mg once daily for 5 days. Uncomplicated skin and skin structure: 500mg once daily for 7–10 days; complicated: 750mg once daily for 7–14 days. Prostatitis: 500mg once daily for 28 days. Uncomplicated UTIs: 250mg once daily for 3 days. Complicated UTIs, acute pyelonephritis: 250mg once daily for 10 days or 750mg once daily for 5 days. Postexposure inhalational anthrax: 500mg once daily for 60 days (start as soon as possible after exposure). Renal impairment (CrCl <50mL/min): reduce dose; see literature. |
| Precautions |
|
Increased risk of tendinitis and tendon rupture esp. in patients >60yrs, or those with kidney, heart or lung transplants. Maintain adequate hydration. Renal impairment. CNS disorders (eg, cerebral arteriosclerosis, epilepsy) that increase seizure risk. Avoid in proarrhythmic conditions (eg, bradycardia, cardiomyopathy) or hypokalemia. Discontinue if rash, jaundice, other signs of hypersensitivity, hypoglycemic reactions, phototoxicity, CNS stimulation, or hepatitis occurs. Discontinue if tendon pain, inflammation or rupture occurs. Monitor blood, renal, hepatic, and hematopoietic function. Reevaluate if peripheral neuropathy occurs. Avoid excessive sun or UV light. Pregnancy (Cat.C), nursing mothers: not recommended. |
| Interactions |
|
Avoid drugs that prolong QT interval (eg, Class IA or Class III antiarrhythmics). Avoid oral form with antacids containing magnesium or aluminum, sucralfate, didanosine, iron, zinc, other metal cations (separate dosing by at least 2 hours). Increased risk of tendinitis and tendon rupture with corticosteroids. Monitor theophylline, warfarin, antidiabetic agents. Caution with other drugs that may lower seizure threshold (eg, NSAIDs). |
| Adverse Reactions |
|
GI upset, CNS stimulation, dizziness, headache, pruritus, rash, abdominal pain, tendinitis/rupture, local reactions (inj); rarely: peripheral neuropathy, hepatotoxicity, photosensitivity, convulsions. Children: also musculoskeletal disorders. |
| How Supplied |
Tabs 250mg, 500mg—50
750mg—20
LEVA-Pak (5 x 750mg tabs)—1
Oral soln—480mL
Inj conc (single-use vials) 20mL, 30mL—1
Inj premixed 50mL, 100mL, 150mL—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
